ArticleAntimicrobial agents and chemotherapy2012
Corifungin, a new drug lead against Naegleria, identified from a high-throughput screen.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 77 citations in OpenAlex.
- The Activity of FDA-Approved Prodrug Isavuconazonium Sulfate and Its Major Metabolite Isavuconazole AgainstPharmaceutics · 2026Article
- Virulence ofbioRxiv : the preprint server for biology · 2025Article
- A review of the mechanism, diagnosis, and treatment ofFrontiers in microbiology · 2025Review
- Next generation imidazothiazole and imidazooxazole derivatives as potential drugs against brain-eating amoebae.Parasitology research · 2024Article
- Miconazole-like Scaffold is a Promising Lead forJournal of medicinal chemistry · 2023Article
- The anti-amoebic potential of carboxamide derivatives containing sulfonyl or sulfamoyl moieties against brain-eating Naegleria fowleri.Parasitology research · 2023Article
- Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes.Frontiers in microbiology · 2023Article
- A Broad Spectrum Antiparasitic Activity of Organotin (IV) Derivatives and Its Untargeted Proteomic Profiling UsingPathogens (Basel, Switzerland) · 2022Article
- Zinc Oxide Nanoconjugates against Brain-Eating Amoebae.Antibiotics (Basel, Switzerland) · 2022Article
- Virtual Screening of Alkaloid and Terpenoid Inhibitors of SMT Expressed inMolecules (Basel, Switzerland) · 2022Article
- Nanovehicles in the improved treatment of infections due to brain-eating amoebae.International microbiology : the official journal of the Spanish Society for Microbiology · 2022Review
- Antiamoebic Properties of Metabolites againstAntibiotics (Basel, Switzerland) · 2022Article
- Opportunistic free-living amoebal pathogens.Pathogens and global health · 2022Article
- Differential Growth Rates andMicrobiology spectrum · 2022Article
- Primary Amoebic Meningoencephalitis byBiomolecules · 2021Review
- Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads.Expert review of anti-infective therapy · 2021Article
- EdU Incorporation To Assess Cell Proliferation and Drug Susceptibility in Naegleria fowleri.Antimicrobial agents and chemotherapy · 2021Article
- HMG-CoA Reductase Inhibitors as Drug Leads againstACS chemical neuroscience · 2020Article
- Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae.PLoS neglected tropical diseases · 2020Article
- Activity of Auranofin against Multiple Genotypes ofACS chemical neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Primary amebic meningoencephalitis (PAM) is a rapidly fatal infection caused by the free-living ameba Naegleria fowleri. The drug of choice in treating PAM is the antifungal antibiotic amphotericin B, but its use is associated with severe adverse effects. Moreover, few patients treated with amphotericin B have survived PAM. Therefore, fast-acting and efficient drugs are urgently needed for the treatment of PAM. To facilitate drug screening for this pathogen, an automated, high-throughput screening methodology was developed and validated for the closely related species Naegleria gruberi. Five kinase inhibitors and an NF-kappaB inhibitor were hits identified in primary screens of three compound libraries. Most importantly for a preclinical drug discovery pipeline, we identified corifungin, a water-soluble polyene macrolide with a higher activity against Naegleria than that of amphotericin B. Transmission electron microscopy of N. fowleri trophozoites incubated with different concentrations of corifungin showed disruption of cytoplasmic and plasma membranes and alterations in mitochondria, followed by complete lysis of amebae. In vivo efficacy of corifungin in a mouse model of PAM was confirmed by an absence of detectable amebae in the brain and 100% survival of mice for 17 days postinfection for a single daily intraperitoneal dose of 9 mg/kg of body weight given for 10 days. The same dose of amphotericin B did not reduce ameba growth, and mouse survival was compromised. Based on these results, the U.S. FDA has approved orphan drug status for corifungin for the treatment of PAM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.